CYP450-based reclassification of urinary metabolic ratio cutoffs for pain management and substance abuse treatment drugs.

Traditional 95 percent reference intervals (RIs) for urinary metabolic ratios (MRs) are useful for identifying unusually slow or fast metabolism, but these do not account for cytochrome P450 (CYP450)-mediated variability in drug metabolism. In this study, we re-evaluated MR cutoff limits for 18 metabolite-parent drug pairs using genotype-predicted phenotype frequencies reported by Zhu et al. These pairs include dextrorphan/dextromethorphan, oxymorphone/oxycodone, hydromorphone/hydrocodone, O-desmethyltramadol/tramadol, hydromorphone/-morphine, norbuprenorphine/buprenorphine, norfentanyl/-fentanyl, -noroxycodone/-oxycodone, norhydrocodone/hydrocodone, -7-aminoclonazepam/clonazepam, α-hydroxyalprazolam/alprazolam, norquetiapine/quetiapine, meprobamate/carisoprodol, N-desmethyltapentadol/tapentadol, norketamine/ketamine, -2-ethylidene-1,5-dimethyl-3,3-diphenylpyrrolidine/methadone, -desipramine/imipramine, and nortriptyline/amitriptyline. Using a dataset of 2.2 million urine drug testing (UDT) specimens collected from pain management and rehabilitation clinics, we calculated new MR cutoffs that reflect CYP phenotype distributions. CYP2D6-metabolized drug pairs showed consistent upward shifts in both lower and upper limits relative to 95 percent RIs; for example, the -dextrorphan/dextromethorphan lower limit increased from 0.157 to 0.277 and the upper limit from 245.140 to 282.448. CYP2C19-metabolized pairs demonstrated minimal changes to lower limits but marked decreases in upper limits, eg, meprobamate/carisoprodol upper limit decreased from 942.04 to 133.44, consistent with the high prevalence of increased-function alleles. For CYP3A4, CYP2C9, and CYP2B6, only lower thresholds could be derived, reflecting the absence of validated ultrarapid metabolizer categories. Across drug pairs, CYP-specific thresholds reclassified 2.99-27.86 percent of specimens that fell outside the CYP-informed limits. MR-derived phenotype classifications aligned with the phenotype frequencies reported in Zhu et al., indicating that population-level MR distributions reflect known CYP450 genetic variability. Incorporating CYP-specific cutoffs alongside traditional 95 percent RIs may improve identification of expected genetic metabolism, reduce misclassification, and enhance the interpretive accuracy of MR analysis in clinical UDT.